RESUMEN
BACKGROUND: Sex-Hormone Binding Globulin (SHBG) may be associated to Pre-eclampsia (PE) and Fetal Growth Restriction (RCIU). AIM: To determine if maternal serum SHBG concentrations during the first and second trimesters are predictive biomarkers of Pre-eclampsia and RCIU. PATIENTS AND METHODS: Prospective cohort study carried out in the Fetal Medicine Unit, Universidad de Chile Clinical Hospital between January, 2005 and December, 2006. Blood samples were obtained from unselected pregnant women during routine 11-14 week and 22-25 week ultrasound examinations, conforming two different study groups. Posteriorly, serum SHBG concentrations were determined in women who developed Pre-eclampsia, RCIU and their respective controls. RESULTS: Fifty five patients were included in the 11-14 weeks group. Nine women that developed PE, 10 that developed RCIU and 36 controls were selected from this group. There were no significant differences in SHBG levels between patients with PE, RCIU or controls (324.7 (26.6), 336.8 (33.9) and 377.5 (24.3) nmol/L, respectively). Fifty four women were included in the 22-25 weeks group. Eight women who developed Pre-eclampsia, 15 who developed RCIU and 31 controls were selected. Again, there were no significant differences in SHBG levels between patients with PE, RCIU or controls (345.5 (151.1), 383.8 (143.4) and 345.5 nmol/l (151.1), respectively). CONCLUSIONS: Maternal SHBG serum levels did not predict subsequent development of Pre-eclampsia and RCIU.
Asunto(s)
Retardo del Crecimiento Fetal/sangre , Preeclampsia/sangre , Globulina de Unión a Hormona Sexual/metabolismo , Adulto , Biomarcadores/sangre , Estudios de Casos y Controles , Femenino , Humanos , Valor Predictivo de las Pruebas , Embarazo , Primer Trimestre del Embarazo , Segundo Trimestre del Embarazo , Factores de Riesgo , Adulto JovenRESUMEN
Background: Sex-Hormone Binding Globulin (SHBG) may be associated to Pre-eclampsia (PE) and Fetal Growth Restriction (RCIU). Aim: To determine if maternal serum SHBG concentrations during the first and second trimesters are predictive biomarkers of Pre-eclampsia and RCIU. Patients and Methods: Prospective cohort study carried out in the Fetal Medicine Unit, Universidad de Chile Clinical Hospital between January, 2005 and December, 2006. Blood samples were obtained from unselectedpregnant women during routine 11-14 week and 22-25 week ultrasound examinations, conforming two different study groups. Posteriorly, serum SHBG concentrations were determined in women who developed Pre-eclampsia, RCIU and their respective controls. Results: Fifty five patients were included in the 11-14 weeks group. Nine women that developed PE, 10 that developed RCIU and 36 controls were selected from this group. There were no significant differences in SHBG levels between patients with PE, RCIU or controls (324.7 (26.6), 336.8 (33.9) and 377.5 (24.3) nmol/L, respectively). Fifty four women were included in the 22-25 weeks group. Eight women who developed Pre-eclampsia, 15 who developed RCIU and 31 controls were selected. Again, there were no significant differences in SHBG levels between patients with PE, RCIU or controls (345.5 (151.1), 383.8 (143.4) and 345.5 nmol/l (151.1), respectively). Conclusions: Maternal SHBG serum levels did not predict subsequent development of Pre-eclampsia and RCIU.
Asunto(s)
Adulto , Femenino , Humanos , Embarazo , Adulto Joven , Retardo del Crecimiento Fetal/sangre , Preeclampsia/sangre , Globulina de Unión a Hormona Sexual/metabolismo , Biomarcadores/sangre , Estudios de Casos y Controles , Valor Predictivo de las Pruebas , Primer Trimestre del Embarazo , Segundo Trimestre del Embarazo , Factores de RiesgoRESUMEN
Acute hepatitis has a very low incidence disease during pregnancy. However, it may be an important cause of jaundice during gestation which in cases of viral etiology can have a very high morbidity and mortality risk to the mother and the fetus. The purpose of this review is to update the available knowledge regarding viral hepatitis during pregnancy including description of the main etiologies, transmission route, maternal-fetal risk and possible management.
La hepatitis aguda es una enfermedad de baja incidencia durante el embarazo; sin embargo, es una causa importante de ictericia durante el desarrollo de éste y en algunos casos presenta un alto riesgo de morbi-mortalidad materno-fetal, siendo la etiología principalmente viral. El propósito de este artículo es actualizar los conocimientos disponibles en la literatura médica respecto a hepatitis viral durante el embarazo, conocer cuáles son los agentes más prevalentes, vía de transmisión, riesgo para el binomio madre- hijo y eventual manejo.
Asunto(s)
Femenino , Humanos , Recién Nacido , Embarazo , Hepatitis Viral Humana , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Complicaciones Infecciosas del Embarazo/virología , Enfermedad Aguda , Hepatitis Viral Humana/diagnóstico , Hepatitis Viral Humana/terapia , Hepatitis Viral Humana/transmisión , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/terapiaRESUMEN
Acute hepatitis has a very low incidence disease during pregnancy. However, it may be an important cause of jaundice during gestation which in cases of viral etiology can have a very high morbidity and mortality risk to the mother and the fetus. The purpose of this review is to update the available knowledge regarding viral hepatitis during pregnancy including description of the main etiologies, transmission route, maternal-fetal risk and possible management.